Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind crossover study of PT001 (glycopyrronium MDI) in Japanese subjects with moderate to severe COPD
jRCT2080224022Phase 2
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224022.